IL243822B - Anti-activin a antibodies and uses thereof - Google Patents

Anti-activin a antibodies and uses thereof

Info

Publication number
IL243822B
IL243822B IL24382216A IL24382216A IL243822B IL 243822 B IL243822 B IL 243822B IL 24382216 A IL24382216 A IL 24382216A IL 24382216 A IL24382216 A IL 24382216A IL 243822 B IL243822 B IL 243822B
Authority
IL
Israel
Prior art keywords
activin
antibodies
Prior art date
Application number
IL24382216A
Other languages
Hebrew (he)
Other versions
IL243822A0 (en
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of IL243822A0 publication Critical patent/IL243822A0/en
Publication of IL243822B publication Critical patent/IL243822B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
IL24382216A 2013-07-30 2016-01-28 Anti-activin a antibodies and uses thereof IL243822B (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361859926P 2013-07-30 2013-07-30
US201361864036P 2013-08-09 2013-08-09
US201361911834P 2013-12-04 2013-12-04
US201361913885P 2013-12-09 2013-12-09
PCT/US2014/048957 WO2015017576A1 (en) 2013-07-30 2014-07-30 Anti-activin a antibodies and uses thereof

Publications (2)

Publication Number Publication Date
IL243822A0 IL243822A0 (en) 2016-04-21
IL243822B true IL243822B (en) 2019-11-28

Family

ID=52427866

Family Applications (2)

Application Number Title Priority Date Filing Date
IL24382216A IL243822B (en) 2013-07-30 2016-01-28 Anti-activin a antibodies and uses thereof
IL270218A IL270218B (en) 2013-07-30 2019-10-27 Anti-activin a antibodies and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL270218A IL270218B (en) 2013-07-30 2019-10-27 Anti-activin a antibodies and uses thereof

Country Status (28)

Country Link
US (4) US9718881B2 (en)
EP (4) EP3730151A1 (en)
JP (5) JP6581085B2 (en)
KR (2) KR102315694B1 (en)
CN (2) CN113845594A (en)
AU (2) AU2014296243B2 (en)
BR (1) BR112016002164B1 (en)
CA (1) CA2920071C (en)
CL (1) CL2016000251A1 (en)
CY (1) CY1123788T1 (en)
DK (1) DK3027209T3 (en)
EA (1) EA037926B1 (en)
ES (1) ES2827673T3 (en)
HK (1) HK1225322A1 (en)
HR (1) HRP20201729T1 (en)
HU (1) HUE052518T2 (en)
IL (2) IL243822B (en)
LT (1) LT3027209T (en)
MX (2) MX371498B (en)
PH (1) PH12016500182A1 (en)
PT (1) PT3027209T (en)
RS (1) RS61124B1 (en)
SG (1) SG11201600731WA (en)
SI (1) SI3027209T1 (en)
TW (2) TWI655207B (en)
UY (1) UY35682A (en)
WO (1) WO2015017576A1 (en)
ZA (1) ZA201601294B (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
CN104844713B (en) 2005-11-23 2021-05-14 阿塞勒隆制药公司 Activin-ActRIIa antagonists and uses thereof for promoting bone growth
CL2007002567A1 (en) 2006-09-08 2008-02-01 Amgen Inc ISOLATED PROTEINS FROM LINK TO ACTIVINE TO HUMAN.
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
BRPI0806861A2 (en) 2007-02-01 2014-08-05 Acceleron Pharma Inc ATIVIN-ACTRIE ANTAGONISTS AND USES TO TREAT OR PREVENT BREAST CANCER
TW201940502A (en) 2007-02-02 2019-10-16 美商艾瑟勒朗法瑪公司 Variants derived from ActRIIB and uses therefor
TWI525102B (en) 2007-02-09 2016-03-11 艾瑟勒朗法瑪公司 Pharmaceutical composition comprising an actriia-fc fusion protein; use of an actriia-fc fusion protein for treatment or prevention of cancer-related bone loss; use of an actriia-fc fusion protein for the treatment or prevention of multiple myeloma
CN103877564A (en) 2007-09-18 2014-06-25 阿塞勒隆制药公司 Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
TWI784538B (en) 2008-08-14 2022-11-21 美商艾瑟勒朗法瑪公司 Use of gdf traps to increase red blood cell levels
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
KR20180026795A (en) 2009-06-12 2018-03-13 악셀레론 파마 인코포레이티드 TRUNCATED ActRIIB-FC FUSION PROTEINS
ES2658292T3 (en) 2009-11-17 2018-03-09 Acceleron Pharma, Inc. ActRIIB proteins and variants and uses thereof with respect to the induction of utrophin for the treatment of muscular dystrophy
JO3340B1 (en) 2010-05-26 2019-03-13 Regeneron Pharma Antibodies to human gdf8
CN103298832A (en) 2010-11-08 2013-09-11 阿塞勒隆制药公司 ACTRIIA binding agents and uses thereof
PT2780368T (en) 2011-11-14 2018-03-22 Regeneron Pharma Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and/or activin a
EP3964224A1 (en) 2012-11-02 2022-03-09 Celgene Corporation Activin-actrii antagonists and uses for use in treating renal disease
TWI655207B (en) 2013-07-30 2019-04-01 再生元醫藥公司 Anti-activin A antibody and use thereof
BR122023023170A2 (en) 2014-06-13 2024-02-20 Acceleron Pharma Inc. USE OF AN ACTRII ANTAGONIST IN THE TREATMENT OR PREVENTION OF SKIN ULCERS ASSOCIATED WITH BETA-THALASSEMIA
US20160075772A1 (en) * 2014-09-12 2016-03-17 Regeneron Pharmaceuticals, Inc. Treatment of Fibrodysplasia Ossificans Progressiva
EA039118B1 (en) * 2015-04-01 2021-12-07 Ридженерон Фармасьютикалз, Инк. Method for treating fibrodysplasia ossificans progressiva
WO2016168613A1 (en) 2015-04-15 2016-10-20 Regeneron Pharmaceuticals, Inc. Methods of increasing strength and functionality with gdf8 inhibitors
CA2984249A1 (en) 2015-04-29 2016-11-03 Regeneron Pharmaceuticals, Inc. Treatment of fibrodysplasia ossificans progressiva
TWI752920B (en) * 2015-10-12 2022-01-21 美商再生元醫藥公司 Antigen-binding proteins that activate the leptin receptor
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
WO2018009732A1 (en) 2016-07-08 2018-01-11 Regeneron Pharmaceuticals, Inc. Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertension
AU2017340504A1 (en) 2016-10-05 2019-04-11 Acceleron Pharma, Inc. Compositions and method for treating kidney disease
EP3525820A4 (en) * 2016-10-17 2020-09-16 Vanderbilt University Human respiratory syncytial virus antibodies and methods of use therefor
AU2017357944A1 (en) * 2016-11-10 2019-06-20 Keros Therapeutics, Inc. Activin receptor type IIa variants and methods of use thereof
DE102018103302A1 (en) * 2018-02-14 2019-08-14 Noonee Ag Portable sitting position help device
US11248044B2 (en) * 2018-03-01 2022-02-15 Regeneron Pharmaceuticals, Inc. Methods for altering body composition by administering a GDF8 inhibitor and an Activin A inhibitor
KR20210020018A (en) 2018-06-13 2021-02-23 리제너론 파마슈티칼스 인코포레이티드 Rodent model of progressive ossification fibrodysplasia
CA3123024A1 (en) 2018-12-18 2020-06-25 Regeneron Pharmaceuticals, Inc. Compositions and methods for enhancing body weight and lean muscle mass using antagonists against leptin receptor, gdf8 and activin a
AU2020284038A1 (en) * 2019-05-30 2021-12-02 Acceleron Pharma Inc. ActRII-binding proteins and uses thereof
WO2021142191A1 (en) 2020-01-08 2021-07-15 Regeneron Pharmaceuticals, Inc. Treatment of fibrodysplasia ossificans progressiva
KR20210095781A (en) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 A multi-specific antibody comprising a fusion construct consisting of a Fab and a bioactive effector moiety
CN115362175A (en) 2020-02-11 2022-11-18 瑞泽恩制药公司 anti-ACVR 1 antibodies and uses thereof
CA3183316A1 (en) 2020-06-18 2021-12-23 Regeneron Pharmaceuticals, Inc. Activin a antibody formulations and methods of use thereof
WO2022040461A1 (en) * 2020-08-20 2022-02-24 Regeneron Pharmaceuticals, Inc. Methods for preventing and treating cardiac dysfunction and covid-19 with activin a antagonists
WO2023022968A2 (en) * 2021-08-16 2023-02-23 Acceleron Pharma Inc. Compositions and methods for treating renal diseases or conditions
CA3235627A1 (en) * 2021-10-18 2023-04-27 Byomass Inc. Anti-activin a antibodies, compositions and uses thereof
WO2023147107A1 (en) 2022-01-31 2023-08-03 Byomass Inc. Myeloproliferative conditions
WO2023154672A2 (en) * 2022-02-14 2023-08-17 Ohio University Methods for regulating muscle performance using fat specific protein 27 (fsp27) compositions
TWI819587B (en) * 2022-04-29 2023-10-21 洪慧妤 Composition for prevention of cancer-induced sarcopenia and use thereof for manufacturing food for prevention of cancer-induced sarcopenia
US20240199728A1 (en) 2022-09-21 2024-06-20 Regeneron Pharmaceuticals, Inc. Methods of treating obesity, diabetes, and liver dysfunction

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US5994618A (en) 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
CA2157577C (en) 1993-03-19 2009-11-17 Se-Jin Lee Growth differentiation factor-8
WO1999056768A1 (en) 1998-05-06 1999-11-11 Metamorphix, Inc. Methods for treating diabetes by inhibiting gdf-8
EA005248B1 (en) 1999-07-20 2004-12-30 Фармекса А/С Method for down-regulating gdf-8 activity
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
US7241444B2 (en) 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
AR047392A1 (en) 2002-10-22 2006-01-18 Wyeth Corp NEUTRALIZATION OF ANTIBODIES AGAINST GDF 8 AND ITS USE FOR SUCH PURPOSES
UA85055C2 (en) 2003-06-02 2008-12-25 Уайт Use of myostatin (gdf8) inhibitor in conjunction with corticosteroid for treating neuromuscular disorder
KR20060120229A (en) 2003-12-31 2006-11-24 쉐링-프라우 리미티드 Neutralizing epitope-based growth enhancing vaccine
CA2558478A1 (en) 2004-03-02 2005-09-15 Acceleron Pharma Inc. Alk7 and myostatin inhibitors and uses thereof
WO2005094446A2 (en) 2004-03-23 2005-10-13 Eli Lilly And Company Anti-myostatin antibodies
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
US20060034831A1 (en) 2004-08-12 2006-02-16 Wyeth Combination therapy for diabetes, obesity and cardiovascular diseases using GDF-8 inhibitors
NZ538097A (en) 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
CA2605723A1 (en) 2005-04-25 2006-11-02 Pfizer Inc. Antibodies to myostatin
CN101379086B (en) 2005-08-19 2013-07-17 惠氏公司 Antagonist antibodies against GDF-8 and uses in treatment of ALS and other GDF-8-associated disorders
JP5052517B2 (en) 2005-10-06 2012-10-17 イーライ リリー アンド カンパニー Anti-myostatin antibody
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
UA98447C2 (en) * 2005-11-23 2012-05-25 Акселерон Фарма Инк. ACTIVIN-ActRIIa ANTAGONISTS AND USES FOR PROMOTING BONE GROWTH
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
JP2009518422A (en) 2005-12-06 2009-05-07 アムジェン インコーポレイテッド Use of myostatin antagonist
CN102585002A (en) 2006-06-02 2012-07-18 瑞泽恩制药公司 High affinity antibodies to human il-6 receptor
AU2007292555B2 (en) 2006-09-05 2012-05-31 Eli Lilly And Company Anti-myostatin antibodies
CL2007002567A1 (en) * 2006-09-08 2008-02-01 Amgen Inc ISOLATED PROTEINS FROM LINK TO ACTIVINE TO HUMAN.
TW201718635A (en) 2007-03-06 2017-06-01 安美基公司 Variant activin receptor polypeptides and uses thereof
PE20091163A1 (en) 2007-11-01 2009-08-09 Wyeth Corp ANTIBODIES FOR GDF8
PE20090982A1 (en) 2007-11-05 2009-08-13 Novartis Ag PIPERIDINE DERIVATIVES AS CHOLESTERYL-ESTER TRANSFER PROTEIN (CETP) INHIBITORS
TWI784538B (en) 2008-08-14 2022-11-21 美商艾瑟勒朗法瑪公司 Use of gdf traps to increase red blood cell levels
EA201791940A3 (en) * 2008-11-26 2018-04-30 Амген Инк. OPTIONS OF POLYPEPTIDES OF ACTIVIN IIB RECEPTOR AND THEIR USE
UY32341A (en) 2008-12-19 2010-07-30 Glaxo Group Ltd NEW ANTIGEN UNION PROTEINS
NO2424895T3 (en) 2009-04-27 2018-02-03
EP2445936A1 (en) 2009-06-26 2012-05-02 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
ES2658292T3 (en) 2009-11-17 2018-03-09 Acceleron Pharma, Inc. ActRIIB proteins and variants and uses thereof with respect to the induction of utrophin for the treatment of muscular dystrophy
JO3340B1 (en) 2010-05-26 2019-03-13 Regeneron Pharma Antibodies to human gdf8
CN103298832A (en) 2010-11-08 2013-09-11 阿塞勒隆制药公司 ACTRIIA binding agents and uses thereof
PT2780368T (en) 2011-11-14 2018-03-22 Regeneron Pharma Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and/or activin a
GR1007832B (en) 2011-11-21 2013-02-14 Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, Activin neutralisers and uses thereof for treatment of diseases associated with aberrant "host defence response" activation
JP6433889B2 (en) 2012-06-15 2018-12-05 ファイザー・インク Improved antagonistic antibodies against GDF-8 and uses thereof
JP2016508504A (en) 2013-02-01 2016-03-22 サンタ マリア バイオセラピューティクス インコーポレイテッド Administration of anti-activin-A compound to a subject
TWI655207B (en) 2013-07-30 2019-04-01 再生元醫藥公司 Anti-activin A antibody and use thereof
US20160075772A1 (en) 2014-09-12 2016-03-17 Regeneron Pharmaceuticals, Inc. Treatment of Fibrodysplasia Ossificans Progressiva
WO2016168613A1 (en) 2015-04-15 2016-10-20 Regeneron Pharmaceuticals, Inc. Methods of increasing strength and functionality with gdf8 inhibitors
US11248044B2 (en) * 2018-03-01 2022-02-15 Regeneron Pharmaceuticals, Inc. Methods for altering body composition by administering a GDF8 inhibitor and an Activin A inhibitor

Also Published As

Publication number Publication date
HRP20201729T1 (en) 2020-12-25
KR102315694B1 (en) 2021-10-21
EA037926B1 (en) 2021-06-08
AU2020200892A1 (en) 2020-03-05
AU2020200892B2 (en) 2022-03-31
CA2920071A1 (en) 2015-02-05
EP4062937A1 (en) 2022-09-28
JP7440464B2 (en) 2024-02-28
JP6923602B2 (en) 2021-08-25
US20230312699A1 (en) 2023-10-05
EP4059520A1 (en) 2022-09-21
CN105592858B (en) 2021-10-01
MX2016001394A (en) 2016-08-03
LT3027209T (en) 2020-12-28
WO2015017576A1 (en) 2015-02-05
PT3027209T (en) 2020-10-22
EP3730151A1 (en) 2020-10-28
IL270218B (en) 2021-01-31
EP3027209A1 (en) 2016-06-08
RS61124B1 (en) 2020-12-31
NZ716854A (en) 2022-03-25
CL2016000251A1 (en) 2017-07-14
JP2022130593A (en) 2022-09-06
US9718881B2 (en) 2017-08-01
JP2020011965A (en) 2020-01-23
ES2827673T3 (en) 2021-05-24
US20180155416A1 (en) 2018-06-07
JP7496387B2 (en) 2024-06-06
TW201602133A (en) 2016-01-16
JP2021176887A (en) 2021-11-11
SI3027209T1 (en) 2020-11-30
US10526403B2 (en) 2020-01-07
IL243822A0 (en) 2016-04-21
MX371498B (en) 2020-01-31
NZ754959A (en) 2022-03-25
JP6581085B2 (en) 2019-09-25
HK1225322A1 (en) 2017-09-08
SG11201600731WA (en) 2016-02-26
AU2014296243A1 (en) 2016-03-03
MX2020001201A (en) 2021-01-28
KR102440044B1 (en) 2022-09-06
US20150037339A1 (en) 2015-02-05
CA2920071C (en) 2023-05-23
US20210163583A1 (en) 2021-06-03
UY35682A (en) 2015-02-27
KR20160030581A (en) 2016-03-18
CY1123788T1 (en) 2022-03-24
AU2014296243B2 (en) 2019-11-21
PH12016500182A1 (en) 2016-04-25
TW201920262A (en) 2019-06-01
ZA201601294B (en) 2017-05-31
EA201690243A1 (en) 2016-06-30
HUE052518T2 (en) 2021-05-28
DK3027209T3 (en) 2020-11-02
JP2016528232A (en) 2016-09-15
EP3027209B1 (en) 2020-09-02
CN113845594A (en) 2021-12-28
KR20210129253A (en) 2021-10-27
TWI655207B (en) 2019-04-01
BR112016002164B1 (en) 2023-12-19
JP2022160619A (en) 2022-10-19
CN105592858A (en) 2016-05-18
BR112016002164A2 (en) 2017-09-12

Similar Documents

Publication Publication Date Title
IL270218B (en) Anti-activin a antibodies and uses thereof
IL261743B (en) Anti-il-33 antibodies and uses thereof
HK1232243A1 (en) Anti-b7-h5 antibodies and their uses -b7-h5
IL261547B (en) Anti-hepcidin antibodies and uses thereof
IL245040B (en) Anti-pdgfr-beta antibodies and uses thereof
IL243974B (en) Anti-prlr antibodies and uses thereof
ZA201508896B (en) Anti-c10orf54 antibodies and uses thereof
SG11201509116VA (en) Anti-tweakr antibodies and uses thereof
EP2953970A4 (en) Transthyretin antibodies and uses thereof
GB201308658D0 (en) Antibodies
GB201315487D0 (en) Antibodies
GB201315486D0 (en) Antibodies
GB201300706D0 (en) Antibody
GB201318283D0 (en) Antibodies

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed